CB-52 is a stable analog of Δ9-tetrahydrocannabinol (THC) and anandamide (AEA) which exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptor with Ki values of 210 and 30 nM, respectively. This compound behaves primarily as a CB1 receptor partial agonist and a CB2 receptor neutral antagonist in vitro.
1 Brizzi, A., Brizzi, V., Cascio, M.G., et al. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. J Med Chem 48 7343-7350 (2005). 2 Cascio, M.G., Bisogno, T., Palazzo, E., et al. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. Br J Pharmacol 149 431-440 (2006).
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.